Table 2

Detailed characteristics of the subjects under study

MEN
 WOMEN


Controls N = 10 Mean ± SD
 Hyperlipemic patients N = 20 Mean ± SD
 p
 Controls N = 20 Mean ± SD
 Hyperlipemic patients N = 20 Mean ± SD
 p
BMI
 25.91 ± 3.58
 28.51 ± 2.60
 0.030
 25.36 ± 3.72
 26.73 ± 3.59
 0.24
HOMA IR
 1.685 ± 0.771
 3.137 ± 1.419
 0.002KS
 1.717 ± 0.893
 2.694 ± 1.011
 0.001KS
QUICKI
 0,3596 ± 0,0263
 0,3266 ± 0,0185
 0,002
 0,3603 ± 0,0281
 0,3332 ± 0,0192
 0,0007
Uric acid (mmol/l)
 270.5 ± 65.4
 379.9 ± 84.2
 0.003
 236.1 ± 67.0
 270.8 ± 58.9***
 0.13
Glycemia (mmol/l)
 5.31 ± 0.53
 6.11 ± 0.95
 0.029KS
 5.26 ± 0.42
 5.85 ± 0.70
 0.0027
Insulin (mIU/l)
 6.96 ± 2.80
 11.43 ± 4.50
 0.016KS
 7.33 ± 3.80
 10.27 ± 3.52
 0.034KS
Proinsulin intact (pmol/l)
 2.68 ± 1.15
 5.51 ± 2.75
 0.012KS
 2.51 ± 1.76
 4.49 ± 3.11
 0.034KS
C-peptide (nmol/l)
 0.66 ± 0.31
 1.11 ± 0.39
 0.0148
 0.75 ± 0.35
 0.92 ± 0.34
 0.22KS
Leptin (ng/ml)
 3.07 ± 3.38
 6.21 ± 3.78
 0.012KS
 16.06 ± 13***
 17.79 ± 5.9**
 0.17KS
TNFα (pg/ml)
 14.2 ± 4.15
 11.52 ± 2.77
 0.063KS
 11.65 ± 6.80
 12.73 ± 9.15
 0.43KS
hFABP (pg/ml)
 3.86 ± 2.47
 4.53 ± 1.97
 0.46
 3.09 ± 1.80
 3.79 ± 2.00
 0.41KS
ACL-IgG (IU/ml)
 13.08 ± 6.75
 19.63 ± 16.9
 0.57KS
 12.28 ± 6.38
 16.35 ± 16.8
 0.99KS

BMI = body mass index, HOMA IR and QUICKI = homeostatic indexes of insulin resistance (see Methods), TNFα = tumor necrosis factor α, hFABP = heart fraction of fatty acid binding protein, ACL-IgG = IgG anticardiolipin. Other designations are the same as in Table 1.

Lichnovská et al. Cardiovascular Diabetology 2002 1:4   doi:10.1186/1475-2840-1-4